Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker RNAC
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | Carsten Brunn President and CEO, Director | RNAC Cartesian Therapeutics, Inc. | Sale | 23,766 | $6.82 | $162.1K Sale | Form 4 ↗ |
| Jan 6, 2026 | Milos Miljkovic Chief Medical Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 3,573 | $6.82 | $24.4K Sale | Form 4 ↗ |
| Jan 6, 2026 | Blaine Davis Chief Financial Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 10,591 | $6.82 | $72.2K Sale | Form 4 ↗ |
| Dec 4, 2025 | Timothy C. Barabe Director | RNAC Cartesian Therapeutics, Inc. | Buy | 30,000 | $6.86 | $205.8K Buy | Form 4 ↗ |
| Apr 11, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 36,338 | $10.77 | $391.4K Buy | Form 4 ↗ |
| Apr 11, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 6,412 | $10.77 | $69.1K Buy | Form 4 ↗ |
| Apr 10, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 3,451 | $10.92 | $37.7K Buy | Form 4 ↗ |
| Apr 10, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 45,144 | $10.43 | $470.9K Buy | Form 4 ↗ |
| Apr 10, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 609 | $10.92 | $6,650 Buy | Form 4 ↗ |
| Apr 10, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 7,966 | $10.43 | $83.1K Buy | Form 4 ↗ |
| Apr 9, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 178 | $9.95 | $1,771 Buy | Form 4 ↗ |
| Apr 9, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 41,604 | $9.43 | $392.3K Buy | Form 4 ↗ |
| Apr 9, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 31 | $9.95 | $308 Buy | Form 4 ↗ |
| Apr 9, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 7,342 | $9.43 | $69.2K Buy | Form 4 ↗ |
| Mar 20, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 54,889 | $15.59 | $855.7K Buy | Form 4 ↗ |
| Mar 19, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 20,234 | $14.97 | $302.9K Buy | Form 4 ↗ |
| Mar 18, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 14,740 | $14.42 | $212.6K Buy | Form 4 ↗ |
| Jan 14, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 4,022 | $18.00 | $72.4K Buy | Form 4 ↗ |
| Jan 13, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 8,983 | $17.78 | $159.7K Buy | Form 4 ↗ |
| Jan 13, 2025 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 7,962 | $16.86 | $134.2K Buy | Form 4 ↗ |
| Jan 6, 2025 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 2,458 | $16.83 | $41.4K Sale | Form 4 ↗ |
| Jan 6, 2025 | Milos Miljkovic Chief Medical Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 948 | $16.83 | $16.0K Sale | Form 4 ↗ |
| Jan 6, 2025 | Christopher M. Jewell Chief Scientific Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 1,286 | $16.83 | $21.6K Sale | Form 4 ↗ |
| Jan 6, 2025 | Emily English Chief Operations Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 906 | $16.83 | $15.2K Sale | Form 4 ↗ |
| Jan 6, 2025 | Carsten Brunn President and CEO, Director | RNAC Cartesian Therapeutics, Inc. | Sale | 8,708 | $16.83 | $146.6K Sale | Form 4 ↗ |
| Jan 6, 2025 | Blaine Davis Chief Financial Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 4,028 | $16.83 | $67.8K Sale | Form 4 ↗ |
| Jan 3, 2025 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 2,417 | $16.72 | $40.4K Sale | Form 4 ↗ |
| Jan 3, 2025 | Milos Miljkovic Chief Medical Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 932 | $16.72 | $15.6K Sale | Form 4 ↗ |
| Jan 3, 2025 | Christopher M. Jewell Chief Scientific Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 1,264 | $16.72 | $21.1K Sale | Form 4 ↗ |
| Jan 3, 2025 | Emily English Chief Operations Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 891 | $16.72 | $14.9K Sale | Form 4 ↗ |
| Jan 3, 2025 | Carsten Brunn President and CEO, Director | RNAC Cartesian Therapeutics, Inc. | Sale | 8,563 | $16.72 | $143.2K Sale | Form 4 ↗ |
| Jan 3, 2025 | Blaine Davis Chief Financial Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 3,961 | $16.72 | $66.2K Sale | Form 4 ↗ |
| Dec 23, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 5,181 | $19.00 | $98.4K Buy | Form 4 ↗ |
| Dec 20, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 21,800 | $18.94 | $412.9K Buy | Form 4 ↗ |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 3,376 | $18.93 | $63.9K Buy | Form 4 ↗ |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 10,529 | $18.35 | $193.2K Buy | Form 4 ↗ |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 11,303 | $17.39 | $196.6K Buy | Form 4 ↗ |
| Dec 10, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 2,901 | $24.35 | $70.6K Sale | Form 4 ↗ |
| Dec 9, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 4,539 | $25.83 | $117.2K Sale | Form 4 ↗ |
| Dec 9, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 6,224 | $25.26 | $157.2K Sale | Form 4 ↗ |
| Nov 21, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 32,789 | $16.67 | $546.6K Sale | Form 4 ↗ |
| Nov 20, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 100 | $18.09 | $1,809 Sale | Form 4 ↗ |
| Nov 20, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 5,600 | $17.28 | $96.8K Sale | Form 4 ↗ |
| Nov 19, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 200 | $19.50 | $3,900 Sale | Form 4 ↗ |
| Nov 18, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 20,181 | $18.42 | $371.7K Buy | Form 4 ↗ |
| Nov 18, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 38,114 | $17.96 | $684.5K Buy | Form 4 ↗ |
| Nov 18, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 17,728 | $18.58 | $329.4K Sale | Form 4 ↗ |
| Nov 18, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 16,672 | $18.19 | $303.3K Sale | Form 4 ↗ |
| Nov 15, 2024 | Timothy A. Springer Director, 10% owner | RNAC Cartesian Therapeutics, Inc. | Buy | 277,246 | $17.09 | $4.7M Buy | Form 4 ↗ |
| Nov 15, 2024 | Metin Kurtoglu Chief Technology Officer | RNAC Cartesian Therapeutics, Inc. | Sale | 22,068 | $17.20 | $379.6K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:35 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances